 |
7 Diseases |  |
1 Trial |
|
1 Trial |  |
163 News |  |
| «12 |
- ||||| Anjeso (meloxicam IV) / Baudax Bio
Trial completion, Trial completion date, Trial primary completion date: Evaluation of Preoperative N1539 in Total Knee Arthroplasty (clinicaltrials.gov) - Nov 15, 2019
P3b, N=194, Completed, Sponsor: Recro Pharma, Inc.
Recruiting --> Completed | Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Oct 2018 --> May 2019
- ||||| Anjeso (meloxicam IV) / Baudax Bio
Trial completion, Surgery: Evaluation of Preoperative N1539 in Colorectal Surgery (clinicaltrials.gov) - Nov 15, 2019
P3, N=55, Completed, Sponsor: Recro Pharma, Inc.
Recruiting --> Completed | Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Oct 2018 --> May 2019 Recruiting --> Completed
- | meloxicam IV (N 1539) / Recro Pharma
Clinical, Journal: COMPARATIVE ANALYSIS OF PREVALENCE OF THE MOST COMMON ALERGY DISEASES IN CHILDREN OF THE KYIV REGION (UKRAINE). (Pubmed Central) - Nov 6, 2019
For comparative analysis, data from asthma, rhinitis and eczema and two age groups of 6-7 years (n=1647) and 13-14 years old (n=1539) were used as required by the design of ISAAC...The steady growth of allergic diseases prevalence requires further investigation of causative factors and possible ways of their solution for both Ukraine as a whole and for the Kyiv region in particular. Worrying problems of insufficient asthma control also flow out from the performed analysis, especially in regards the adolescent age category, which determines the future research directions.
- || meloxicam NanoCrystal intravenous (N 1539) / Recro Pharma
NDA: $REPH FDA Grants Appeal of CRL for IV Meloxicam NDA https://t.co/klOnPwh7x5 (Twitter) - Oct 31, 2019
- | meloxicam NanoCrystal intravenous (N 1539) / Recro Pharma
Clinical, Journal: Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-Controlled Trial. (Pubmed Central) - Oct 12, 2019
The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/.
- | Clinical, Journal: Analgesic Efficacy of Bupivacaine or Bupivacaine-Dexmedetomidine After Intraperitoneal Administration in Cats: A Randomized, Blinded, Clinical Trial. (Pubmed Central) - Oct 3, 2019
Sedation scores were not significantly different between groups throughout the study. In terms of prevalence of rescue analgesia, but not duration of action, the analgesic efficacy of bupivacaine-dexmedetomidine was similar to bupivacaine alone after intraperitoneal administration in cats receiving buprenorphine.
- | meloxicam NanoCrystal intravenous (N 1539) / Recro Pharma
Clinical, Journal: Noninfectious complications of acute stroke and their impact on hospital mortality in patients admitted to a stroke unit in Warsaw from 1995 to 2015. (Pubmed Central) - May 29, 2019
Over the last two decades Polish urban stroke units may have achieved a significant reduction of the occurrence of some noninfectious complications (i.e. MI, exacerbated CHF and DVT). However, the list of conditions associated with stroke unit mortality includes not only MI and exacerbated CHF but also PE, gastrointestinal bleeding and recurrent stroke.
- | meloxicam NanoCrystal intravenous (N 1539) / Recro Pharma
Clinical, Journal: A Randomized Double-Blind Controlled Trial of Intravenous Meloxicam in the Treatment of Pain Following Dental Impaction Surgery. (Pubmed Central) - Apr 19, 2019
P2
Nausea was the most commonly reported treatment-emergent adverse event. NCT00945763.
- | Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam https://t.co/bsYoNTQmCI #PinkSheet (Twitter) - Mar 25, 2019
- |||||| Anjeso (meloxicam IV) / Baudax Bio
Enrollment open: Evaluation of Preoperative N1539 in Total Knee Arthroplasty (clinicaltrials.gov) - Feb 23, 2018
P3b, N=200, Recruiting, Sponsor: Recro Pharma, Inc.
NCT00945763. Not yet recruiting --> Recruiting
- |||||||||| Anjeso (meloxicam IV) / Baudax Bio
New P3 trial: Evaluation of Preoperative N1539 in Total Knee Arthroplasty (clinicaltrials.gov) - Feb 14, 2018
P3b, N=200, Not yet recruiting, Sponsor: Recro Pharma, Inc.
- ||| Anjeso (meloxicam IV) / Baudax Bio
New P3 trial, Surgery: Evaluation of Preoperative N1539 in Colorectal Surgery (clinicaltrials.gov) - Oct 26, 2017
P3, N=50, Recruiting, Sponsor: Recro Pharma, Inc.
- ||||||| Anjeso (meloxicam IV) / Baudax Bio
Trial completion, Surgery: Evaluation of N1539 Following Major Surgery (clinicaltrials.gov) - May 17, 2017
P3, N=722, Completed, Sponsor: Recro Pharma, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Anjeso (meloxicam IV) / Baudax Bio
Enrollment closed, Surgery: Evaluation of N1539 Following Major Surgery (clinicaltrials.gov) - Mar 7, 2017
P3, N=700, Active, not recruiting, Sponsor: Recro Pharma, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Anjeso (meloxicam IV) / Baudax Bio
Trial completion, Surgery: Evaluation of N1539 Following Abdominoplasty Surgery (clinicaltrials.gov) - Dec 16, 2016
P3, N=219, Completed, Sponsor: Recro Pharma, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Anjeso (meloxicam IV) / Baudax Bio
Enrollment closed, Surgery: Evaluation of N1539 Following Abdominoplasty Surgery (clinicaltrials.gov) - Nov 14, 2016
P3, N=200, Active, not recruiting, Sponsor: Recro Pharma, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Anjeso (meloxicam IV) / Baudax Bio
Trial completion, Trial primary completion date, Surgery: Evaluation of N1539 Following Bunionectomy Surgery (clinicaltrials.gov) - Aug 4, 2016
P3, N=201, Completed, Sponsor: Recro Pharma, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016
- |||||||||| Anjeso (meloxicam IV) / Baudax Bio
New P3 trial, Surgery: Evaluation of N1539 Following Major Surgery (clinicaltrials.gov) - Mar 28, 2016
P3, N=700, Recruiting, Sponsor: Recro Pharma, Inc.
- |||||||||| Anjeso (meloxicam IV) / Baudax Bio
New P3 trial, Surgery: Evaluation of N1539 Following Abdominoplasty Surgery (clinicaltrials.gov) - Feb 9, 2016
P3, N=200, Recruiting, Sponsor: Recro Pharma, Inc.
- |||||||||| Anjeso (meloxicam IV) / Baudax Bio
New P3 trial, Surgery: Evaluation of N1539 Following Bunionectomy Surgery (clinicaltrials.gov) - Feb 5, 2016
P3, N=200, Recruiting, Sponsor: Recro Pharma, Inc.
- |||| Anjeso (meloxicam IV) / Baudax Bio
Trial completion, Surgery: Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery (clinicaltrials.gov) - Jan 19, 2016
P2, N=59, Completed, Sponsor: Recro Pharma, Inc.
Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016 Active, not recruiting --> Completed
- ||| Anjeso (meloxicam IV) / Baudax Bio
Enrollment closed, Surgery: Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery (clinicaltrials.gov) - Nov 24, 2015
P2, N=60, Active, not recruiting, Sponsor: Recro Pharma, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Anjeso (meloxicam IV) / Baudax Bio
New P2 trial, Surgery: Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery (clinicaltrials.gov) - Sep 3, 2015
P2, N=60, Recruiting, Sponsor: Recro Pharma, Inc.
- Anjeso (meloxicam IV) / Baudax Bio
Trial termination, Surgery: Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery (clinicaltrials.gov) - Mar 11, 2012
P3, N=50, Terminated, Sponsor: Alkermes
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- Anjeso (meloxicam IV) / Baudax Bio
Enrollment change, Surgery: Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery (clinicaltrials.gov) - Mar 4, 2012
P3, N=50, Terminated, Sponsor: Alkermes
Active, not recruiting --> Terminated N=250 --> 50
- Anjeso (meloxicam IV) / Baudax Bio
New P3 trial, Surgery: Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery (clinicaltrials.gov) - Sep 14, 2011
P3, N=50, Terminated, Sponsor: Alkermes